Biological Explanations of OCD

Biological Treatment of OCD: Drug Therapy

The biological approach to treating OCD focuses primarily on pharmacological interventions that address the neurochemical imbalances proposed to underlie the disorder. The principal class of drugs used are selective serotonin reuptake inhibitors (SSRIs), which address the serotonin deficiency hypothesised to contribute to OCD. A longer-established alternative, the tricyclic antidepressant clomipramine, is also used where SSRIs are ineffective or not tolerated.

SSRIs: Mechanism of Action

Serotonin is a neurotransmitter that is released by a pre-synaptic neuron into the synaptic cleft, where it binds to receptors on the post-synaptic neuron. After this, serotonin is normally reuptaken (reabsorbed) back into the pre-synaptic neuron for reuse — a process that limits the duration and intensity of serotonergic signalling. SSRIs (such as fluoxetine, sertraline, and fluvoxamine) work by blocking this reuptake mechanism, leaving serotonin in the synaptic cleft for longer and allowing it to continue binding to post-synaptic receptors. This increases the effective level of serotonin activity in serotonergic circuits — including those in the OFC-caudate loop implicated in OCD. Over time (typically 8–12 weeks), this increased serotonin activity appears to reduce the frequency and intensity of obsessional thoughts and the urge to perform compulsions.

Clomipramine

Clomipramine is a tricyclic antidepressant that also strongly inhibits serotonin reuptake (as well as affecting other neurotransmitters including noradrenaline). It was the first drug shown to be specifically effective for OCD — several decades before SSRIs became available. Clomipramine is still used when SSRIs are insufficient, typically in combination with an SSRI or as a standalone treatment, but it has a more significant side effect profile than SSRIs (including sedation, cardiac effects, and anticholinergic effects) which limits its tolerability.

Evidence of Effectiveness

Clinical trials demonstrate that SSRIs produce significant reductions in OCD symptoms, typically assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Meta-analyses (e.g. Abramowitz, 1997) confirm SSRIs are more effective than placebo and equivalent to each other in efficacy. Response rates are moderate — approximately 40–60% of patients show clinically significant improvement — and symptom reduction is typically partial rather than complete elimination. Clomipramine has historically shown slightly higher efficacy than individual SSRIs but this advantage is offset by its greater side effect burden.

Evaluation

Drug therapy for OCD has clear advantages: it is accessible, requires no active engagement on the patient's part, and takes effect relatively quickly compared to therapy. However, drug treatments do not address the underlying cognitive and behavioural maintenance factors (catastrophic misinterpretation, compulsive avoidance), and symptoms often return when medication is discontinued — suggesting drugs suppress rather than resolve the disorder. Side effects (nausea, insomnia, sexual dysfunction with SSRIs; more severe cardiac and anticholinergic effects with clomipramine) affect adherence. Evidence consistently shows that the most effective treatment for moderate to severe OCD is a combination of SSRIs and CBT (specifically exposure and response prevention — ERP), with combined treatment producing the greatest gains and the most durable outcomes.